TITLE:
Multicenter Analysis of mFOLFOX6 with Oxaliplatin Stop-and-Go Strategy Using Oral Uracil-Tegafur with Leucovorin for Unresectable Colorectal Cancer in Elderly Patients
AUTHORS:
Tetsu Yamamoto, Kuniyuki Katano, Shinichi Sugimoto, Akiyoshi Kanazawa, Eiji Hira, Hiroshi Takeda, Yoshitoshi Sato, Yutaka Yamashiro, Yoshitsugu Tajima, Masahide Ikeguchi
KEYWORDS:
Colorectal Cancer; Oxaliplatin; Uracil-Tegafur (UFT); Leucovorin; Elderly Patient; Stop-and-Go
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.2,
February
10,
2014
ABSTRACT: Background: This study evaluated the tolerability
and efficacy of intermittent oxaliplatin treatment based on mFOLFOX6 using oral
uracil-tegafur(UFT) and leucovorin(LV) maintenance therapy in the treatment of
elderly patients with advanced colorectal cancer. Methods: Ten non-elderly patients (70
years) with advanced/recurrent colorectal cancer were enrolled in this
prospective, multicenter cooperative group clinical trial. The mFOLFOX6 regimen
was administered for eight cycles with maintenance therapy with oral UFT/LV
treatment until progression. In cases with disease progression, mFOLFOX6 was
reintroduced. Results: Grade 2 peripheral neuropathy was
noted in 30.0% and 25.0% of the elderly and non-elderly patients, respectively.
The observed time to treatment failure (TTF) was 6.3 months in the elderly
patients and 6.4 months in the non-elderly patients. The disease control rate
was 83.3% in each group. Conclusion: Our new stop-and-go strategy
using oral UFT/LV is well-tolerated and effective even in elderly patients.